Holen Sie sich die Stockscreener-App
178.55
4.18%
8.28
Schlusskurs vom Vortag:
$170.27
Offen:
$185.02
24-Stunden-Volumen:
1.35M
Relative Volume:
0.49
Marktkapitalisierung:
$38.04B
Einnahmen:
$447.02M
Nettoeinkommen (Verlust:
$-1.18B
KGV:
-28.89
EPS:
-6.1812
Netto-Cashflow:
$-906.14M
1W Leistung:
+0.15%
1M Leistung:
-8.65%
6M Leistung:
+83.87%
1J Leistung:
+169.90%
1-Tages-Spanne:
$169.00
$186.19
1-Wochen-Bereich:
$167.39
$186.19
52-Wochen-Spanne:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Vergleichen Sie INSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
178.34 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.60 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
818.73 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.49 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
810.78 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
339.17 | 35.45B | 4.98B | 69.59M | 525.67M | 0.5197 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insmed Incorporated Provides Revenue Guidance for the Full Year 2025 - MarketScreener
Insmed (INSM) Projects Arikayce Revenue of $450M-$470M for FY26 - GuruFocus
INSM Projects Brinsupri Revenue to Reach $172.7 Million by FY25 - GuruFocus
Insmed stock rises after strong BRINSUPRI launch, ARIKAYCE revenue beat By Investing.com - Investing.com UK
Insmed reports strong Q4 revenue for BRINSUPRI and ARIKAYCE By Investing.com - Investing.com UK
Insmed Inc Provides Business Update at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Insmed chief legal officer Smith sells $549k in stock By Investing.com - Investing.com Canada
Why Insmed Incorporated (IM8N) stock remains top ratedVolume Spike & Short-Term Trading Opportunity Alerts - ulpravda.ru
Insmed chief medical officer Flammer sells $2.8m in stock - Investing.com
Insmed COO Adsett sells $747k in stock By Investing.com - Investing.com Canada
Insmed CFO Bonstein sells $808,733 in stock - Investing.com
INSMED Executives Conduct Series of Stock Transactions - TradingView — Track All Markets
Insmed Insider Sold Shares Worth $549,494, According to a Recent SEC Filing - MarketScreener
Published on: 2026-01-09 00:10:22 - ulpravda.ru
Analysis Recap: Is Insmed Incorporated stock a good choice for value investors2025 Fundamental Recap & AI Powered Market Entry Strategies - ulpravda.ru
Will Insmed Incorporated stock outperform tech sector in 20252025 Market Outlook & Real-Time Stock Price Movement Reports - ulpravda.ru
Will Insmed Incorporated stock recover faster than peersJuly 2025 Summary & Long-Term Investment Growth Plans - ulpravda.ru
Published on: 2026-01-08 19:10:10 - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - PR Newswire
Jim Cramer on Insmed: "This One Is Worth Keeping an Eye On" - Finviz
Jim Cramer on Insmed: “This One Is Worth Keeping an Eye On” - Insider Monkey
RBC Lifts Price Target on Insmed to $197 From $195, Keeps Outperform Rating - MarketScreener
How analysts rate Insmed Incorporated stock todayInterest Rate Changes & Affordable Trading Techniques - ulpravda.ru
Non-Cystic Fibrosis Bronchiectasis Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed - Barchart.com
What Catalysts Are Quietly Shifting The Narrative For Insmed (INSM)? - Yahoo Finance
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Insmed Insider Sold Shares Worth $15,293,422, According to a Recent SEC Filing - marketscreener.com
INSM: UBS Lowers Price Target While Maintaining 'Buy' Rating | I - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed ... - Bluefield Daily Telegraph
UBS Adjusts Price Target on Insmed to $215 From $223, Maintains Buy Rating - MarketScreener
Insmed stock price target reiterated at $195 by Leerink on Brinsupri launch - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Market Review: Why Insmed Incorporated IM8N stock remains top ratedAnalyst Downgrade & High Conviction Investment Ideas - moha.gov.vn
Allspring Global Investments Holdings LLC Decreases Holdings in Insmed, Inc. $INSM - MarketBeat
INSM Stock Up 78% in 6 Months: Here's What You Need to Know - Finviz
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Insmed Earnings Notes - Trefis
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Calamos Advisors LLC Acquires 12,263 Shares of Insmed, Inc. $INSM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Insmed Incorporated (INSM) And Encourages Investors to Connect - ACCESS Newswire
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm - Business Wire
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Insmed's chief medical officer sells $2.97 million in stock - MSN
Insmed Incorporated (INSM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INSM Quantitative Stock Analysis - Nasdaq
Rice Hall James & Associates LLC Sells 7,103 Shares of Insmed, Inc. $INSM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
A Closer Look at Insmed's Options Market DynamicsInsmed (NASDAQ:INSM) - Benzinga
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
NASDAQ adding Alnylam, Ferrovial, Insmed, Monolithic Power at open on 12/22 - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Investors to Inquire about Securities Investigation - ACCESS Newswire
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):